A comprehensive view of BioNTech SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
US Patent Issued to GENMAB, BioNTech on March 26 for "Multispecific antibodies against CD40 and CD137" (Dutch, German Inventors)
Published:
March 27, 2024
by U.S. Fed News
|
BioNTech receives a notice of default from the NIH over allegedly owed vaccine royalties under a prior licensing agreement
Published:
March 25, 2024
by FiercePharma
|
INTERNATIONAL PATENT: BIONTECH SE, TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH FILES APPLICATION FOR "SYSTEMS AND COMPOSITIONS COMPRISING TRANS-AMPLIFYING RNA VECTORS WITH MIRNA"
Published:
March 25, 2024
by U.S. Fed News
|
BioNTech reports Q4 net profit of US$497.0M, Q4 revenue of US$1.6B; full-year net income drops 90% year-over-year to US$1.0B, revenue down 90% YoY to US$4.14B
Published:
March 20, 2024
by Benzinga Lightning Feed
|
BioNTech announces fourth quarter and full year 2023 financial results and corporate update
Published:
March 20, 2024
by BioNTech SE
|
Ask us about our Government & Public Policy market view